Skip Navigation

Annals of Oncology 2004 15(9):1443-1444; doi:10.1093/annonc/mdh357
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Apolone, G.
Right arrow Articles by Buda, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apolone, G.
Right arrow Articles by Buda, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?

The first 10% of the full text of this article appears below.

ten Bokkel Huinink et al., on behalf of the International Topotecan Group, have recently published a paper on the long-term outcomes of 226 patients with advanced epithelial ovarian cancer who failed one prior platinum-based regimen and were enrolled in a multicentre randomised phase III study comparing topotecan versus paclitaxel as second-line therapy [1Go].

This study is an update of a study whose main results were previously published in 1997 and 2001 [2Go, 3Go]. In the first paper, activity (response rate, duration of . . . [Full Text of this Article]

G. Apolone* and A. Buda

Department of Oncology, Istituto di Ricerche Farmacologiche 'Mario Negri', Via Eritrea 62, 20157 Milan,Italy

* Email: apolone@marionegri.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?